Healthcare Business

Pills

Short Sellers More Selective on Big Pharma Stocks

The short interest data has been released for the May 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Biotechnology word cloud

Short Sellers Get Even More Ambitious Against Biotech Leaders

The short interest data are out for the May 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
biotech

The Most Loved Biotechs of Big Hedge Funds

With such a mixed performance over the past decade, some of us wonder why hedge funds are so revered. Ditto for many of the so-called guru fund managers. Still, investors ...
Read Full Story »
Eli Lilly Logo

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair share ...
Read Full Story »
road fork sign

Why Baxter May Be Very Undervalued Into Breakup

Baxter International Inc. (NYSE: BAX) is set to break up into two companies on or around July 1, 2015. While there have been many assumptions built into the outlook of ...
Read Full Story »
DNA

How to Evaluate a 50% Move in AVEO

When investors see stocks run up 50% or more on a news release, they probably just assume the company is being acquired. AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) saw its shares ...
Read Full Story »
investing

Has MannKind Stock Finally Bottomed Out?

MannKind Corp. (NASDAQ: MNKD) is just about as controversial of a company as you will find today when it comes to biotech and pharma. Its recently launched Afrezza has had ...
Read Full Story »
fda_logo

How Sarepta Short Interest Is Adding to Its Gains

Usually, when biotech companies meet with the U.S. Food and Drug Administration (FDA), their stock goes one of two ways. In the case of Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares ...
Read Full Story »
Prescription drugs

Can Another 10 Blockbuster Drugs Really Come From Johnson & Johnson in 5 Years?

Johnson & Johnson (NYSE: JNJ) has been working on its pipeline for a while, and plans on continuing to do so. In an effort to strengthen its portfolio, this pharmaceutical ...
Read Full Story »
biotech

Is This the End of the Growth Phase for Intercept?

Investors are not too happy with Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) after it released the terms for its most recent clinical trial. Over the course of 2015, shares have nearly ...
Read Full Story »
Sad lonely pensive old senior woman

What This New Trial Means for Eleven Biotherapeutics

Biotechs are generally riskier companies. A single failed trial can make or break a company. Eleven Biotherapeutics Inc. (NASDAQ: EBIO) felt this pressure when it released its most recent clinical ...
Read Full Story »
Prescription drugs

The 5 Winners and Losers From ASCO Presentations

With the American Society of Clinical Oncology (ASCO) annual meeting just two weeks away, investors, doctors and cancer patients are anxiously awaiting some of the key presentations and abstracts that ...
Read Full Story »
Pentagon, defense

AcelRX Takes Flight With New Department of Defense Contract

A number of pharmaceutical companies are working toward a better solution to manage pain. AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) is one of them, but what separates it from the pack ...
Read Full Story »
research

Analyst Issues 5 Potential Biotech Buyout Candidates

We have said it before, and we will stress it once again, one of the best ways for big pharmaceuticals and biotech companies to grow is through acquisitions. In a ...
Read Full Story »
153576724

Are Problems at Orexigen Still Just Getting Started?

Orexigen Therapeutics Inc. (NASDAQ: OREX) had to bite the bullet Tuesday when it announced that it would be terminating its cardiovascular outcomes study of the obesity drug Contrave. However, things ...
Read Full Story »